The world apheresis association registry, 2023 update

• Published in: Transfusion and apheresis science Vol. 62; no. 6; p. 103831
• Main Authors: Vrielink, Hans, Le Poole, Kaatje, Stegmayr, Bernd, Kielstein, Jan, Berlin, Gösta, Ilhan, Osman, Seval, Guldane Cengiz, Prophet, Heinrich, Aandahl, Astrid, Deeren, Dries, Bojanic, Ines, Blaha, Milan, Lanska, Miriam, Gasova, Zdenka, Bhuiyan-Ludvikova, Zdenka, Blahutova, Sarka, Hrdlickova, Radomira, Audzijoniene, Judita, Griskevicius, Antanas, Glatt, Tanya, Strineholm, Virginia, Ott, Michael, Nilsson, Thomas, Newman, Elizabeth, Derfler, Kurt, Witt, Volker, Toss, Fredrik
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.12.2023
• Subjects: Adverse events; Apheresis; Indications; Procedures; Register; Indications; Procedures; Adverse events; Apheresis; Register
• ISSN: 1473-0502; 1878-1683; 1878-1683
• DOI: 10.1016/j.transci.2023.103831

The WAA apheresis registry contains data on more than 140,000 apheresis procedures conducted in 12 different countries. The aim is to give an update of indications, type and number of procedures and adverse events (AEs). The WAA-registry is used for registration of apheresis procedures and is free of charge. The responsible person for a center can apply at the site www.waa-registry.org Data includes reported AEs from 2012 and various procedures and diagnoses during the years 2018–2022; the latter in total from 27 centers registered a total of 9500 patients (41% women) that began therapeutic apheresis (TA) during the period. A total of 58,355 apheresis procedures were performed. The mean age was 50 years (range 0–94). The most common apheresis procedure was stem cell collection for which multiple myeloma was the most frequent diagnosis (51%). Donor cell collection was done in 14% and plasma exchange (PEX) in 28% of patients; In relation to all performed procedures PEX, using a centrifuge (35%) and LDL-apheresis (20%) were the most common. The main indication for PEX was TTP (17%). Peripheral veins were used in 56% as the vascular access. The preferred anticoagulant was ACD. AEs occurred in 2.7% of all procedures and were mostly mild (1%) and moderate 1.5% (needed supportive medication) and, only rarely, severe (0.15%). The data showed a wide range of indications and variability in apheresis procedures with low AE frequency.